ABVC BioPharma Reports 179% Increase in Total Assets to $21.06 Million, Strengthens Asset-Backed Licensing Model

ABVC BioPharma reported a 179% increase in total assets to $21.06 million, driven by a 2,500% year-over-year increase in net property and equipment to $12.84 million. The company's licensing structure, which separates development risk from long-term value participation, has enabled it to reduce direct clinical cash burn exposure while retaining licensing economics and equity participation. ABVC is strengthening its long-term infrastructure positioning in Asia through strategic land asset acquisitions, with a recent acquisition of 5,995.41 square meters of land in Taiwan valued at $4.6 million.